Kairos Pharma Ltd. (KAPA)
Kairos Pharma Statistics
Share Statistics
Kairos Pharma has 16.69M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 16.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 629 |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -6.63 and the forward PE ratio is -2.05. Kairos Pharma's PEG ratio is -0.19.
| PE Ratio | -6.63 |
| Forward PE | -2.05 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 3.61 |
| P/FCF Ratio | -4.36 |
| PEG Ratio | -0.19 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kairos Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.2, with a Debt / Equity ratio of 0.
| Current Ratio | 4.2 |
| Quick Ratio | 4.2 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 66.94 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.6M |
| Employee Count | 1 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 2.87, so Kairos Pharma's price volatility has been higher than the market average.
| Beta | 2.87 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 40.76 |
| Average Volume (20 Days) | 392.14K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -2.34M |
| Net Income | -2.6M |
| EBITDA | -2.34M |
| EBIT | -2.64M |
| Earnings Per Share (EPS) | -0.23 |
Balance Sheet
The company has 1.27M in cash and 0 in debt, giving a net cash position of 1.27M.
| Cash & Cash Equivalents | 1.27M |
| Total Debt | 0 |
| Net Cash | 1.27M |
| Retained Earnings | -8.81M |
| Total Assets | 5.77M |
| Working Capital | 3.18M |
Cash Flow
In the last 12 months, operating cash flow was -3.96M and capital expenditures 0, giving a free cash flow of -3.96M.
| Operating Cash Flow | -3.96M |
| Capital Expenditures | 0 |
| Free Cash Flow | -3.96M |
| FCF Per Share | -0.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KAPA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for KAPA is $9, which is 934.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 934.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 5.47 |
| Piotroski F-Score | 1 |